Evidence map›Paper›PMID 31905601›Full record

ArticleInternational journal of molecular sciences2019

Differential Transcription of SOCS5 and SOCS7 in Multiple Sclerosis Patients Treated with Interferon Beta or Glatiramer Acetate.

Emmanuel Rojas-Morales, Gerardo Santos-López, Samuel Hernández-Cabañas, Raúl Arcega-Revilla, Nora Rosas-Murrieta, Carolina Jasso-Miranda, Elie Girgis El-Kassis, Julio Reyes-Leyva, Virginia Sedeño-Monge

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.1field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Emmanuel Rojas-MoralesDecanato de Ciencias de la Salud, Facultad de Medicina, Universidad Popular Autónoma del Estado de Puebla, Puebla 72410, Mexico.
Gerardo Santos-LópezLaboratorio de Biología Molecular y Virología, Centro de Investigación Biomédica de Oriente, Instituto Mexicano del Seguro Social, Metepec, Puebla 74360, Mexico.ORCID 0000-0002-3793-3117
Samuel Hernández-CabañasInstituto Mexicano del Seguro Social, Puebla 72560, Mexico.
Raúl Arcega-RevillaInstituto Mexicano del Seguro Social, Puebla 72560, Mexico.
Nora Rosas-MurrietaLaboratorio de Bioquímica y Biología Molecular, Centro de Química, Instituto de Ciencias, Benemérita Universidad Autónoma de Puebla, Puebla 72570, Mexico.ORCID 0000-0002-4605-670X
Carolina Jasso-MirandaLaboratorio de Biología Molecular y Virología, Centro de Investigación Biomédica de Oriente, Instituto Mexicano del Seguro Social, Metepec, Puebla 74360, Mexico.ORCID 0000-0002-4075-0231
Elie Girgis El-KassisDecanato de Ciencias Biológicas, Universidad Popular Autónoma del Estado de Puebla, Puebla 72410, Mexico.
Julio Reyes-LeyvaLaboratorio de Biología Molecular y Virología, Centro de Investigación Biomédica de Oriente, Instituto Mexicano del Seguro Social, Metepec, Puebla 74360, Mexico.
Virginia Sedeño-MongeDecanato de Ciencias de la Salud, Facultad de Medicina, Universidad Popular Autónoma del Estado de Puebla, Puebla 72410, Mexico.ORCID 0000-0003-4294-9268
Mexican Social Security Institute · MXUniversidad Popular Autónoma del Estado de Puebla · MXBenemérita Universidad Autónoma de Puebla · MX

Funding

UNIVERSIDAD POPULAR AUTONOMA DEL ESTADO DE PUEBLA, FONDO EDITORIAL Y DE INVESTIGACION FEI2015
6 · The paper itself

Abstract

The participation of proinflammatory cytokines in the progression of Multiple Sclerosis (MS) has been well documented. Cytokines activate the JAK-STAT pathway, in which the suppressors of cytokine signaling (SOCS) exert a negative feedback. This paper analyzes the levels of SOCS5 and SOCS7 transcripts, quantified by RT-qPCR, in MS patients, and the concentrations of proinflammatory cytokines, IFN-

Indexed as

AdultFemaleGlatiramer AcetateHumansImmunologic FactorsImmunosuppressive AgentsInterferon-betaInterferon-gammaMaleMiddle AgedMultiple Sclerosis, Relapsing-RemittingRNA, MessengerSuppressor of Cytokine Signaling ProteinsGlatiramer AcetateImmunologic FactorsImmunosuppressive AgentsInterferon-betaInterferon-gammaRNA, MessengerSOCS5 protein, humanSOCS7 protein, humanSuppressor of Cytokine Signaling Proteinsglatiramer acetateIFN-βJAK-STATmultiple sclerosisSOCS5SOCS7

Identifiers

PMID31905601
PMCPMC6982240
OpenAlexW2998181538

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.